BIOLOGICAL EVALUATION OF MITO-SG1 AS A POTENT CYTOTOXIC AGENT IN THE TREATMENT OF GASTRIC CANCER

• DOI: 10.22533/at.ed.1112331087

• Palavras-chave: -

• Keywords: Mito-SG1, Gastric Cancer, Mitochondria, Selective Treatment

• Abstract:

  Gastric cancer (CG) ranks third in cancer deaths and fifth in new cases each year in the
  world. In Colombia, CG has reached first place in deaths and third place in new cases each
  year. Recent studies have reported factors that lead to its development, great genetic variety,
  high concentration of reactive oxygen species (ROS), hyperpolarization of the membrane,
  lower oxygen consumption, and greater glycolysis compared to healthy gastric epithelial
  cells; in addition, mitochondrial dysfunction that promotes cell migration and accelerates
  invasion through ROS. New compounds called “mito-compounds” have been designed to
  act on these factors to induce cell death by apoptosis. Mito-SG1 is a mito-compound that
  showed antitumor effects in triple-negative breast cancer. We evaluated Mito-SG1 in AGS
  (adherent CG cell line) and KATO III (semi-adherent CG cell line). Mito-SG1 inhibited cell
  growth, induced a concentration-dependent change in mitochondrial membrane potential
  (Δψm), and increased ROS production. It was seen in real time that Mito-SG1 significantly
  decreased mitochondrial bioenergetics of AGS and KATO III in a dose-time-dependent

  manner. Mito-SG1 induced cell death by intrinsic apoptosis. Mito-SG1 may be an alternative
  in the treatment of CG and may be used concomitantly with 5-Fluorouracil (5-FU) and
  Sorafenib.